Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial

OBJECTIVE: This study aimed to evaluate the safety, efficacy, and feasibility of the rituximab, fotemustine, pemetrexed, and dexamethasone (R-FPD) regimen followed by whole-brain radiotherapy (WBRT) for patients with primary central nervous system lymphoma (PCNSL). METHODS: A prospective, single-cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jingjing, Gao, Fenghua, Wang, Wenhua, Zhang, Xudong, Dong, Meng, Zhang, Lei, Li, Xin, Li, Ling, Sun, Zhenchang, Wang, Xinhua, Fu, Xiaorui, Zhu, Linan, Ding, Mengjie, Niu, Songtao, Li, Zhaoming, Chang, Yu, Nan, Feifei, Yan, Jiaqian, Yu, Hui, Wu, Xiaolong, Zhou, Zhiyuan, Zhang, Jieming, Zhang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334761/
https://www.ncbi.nlm.nih.gov/pubmed/34633776
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334761/
https://www.ncbi.nlm.nih.gov/pubmed/34633776
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0026

Ejemplares similares